Details for New Drug Application (NDA): 065220
✉ Email this page to a colleague
NDA 065220 describes NEOMYCIN SULFATE, which is a drug marketed by Adrastea Pharma, Bristol Myers Squibb, Chartwell Molecular, Lannett, Lilly, Nostrum Labs Inc, Roxane, Sandoz, Teva, Bausch And Lomb, Pharmafair, Alcon Pharms Ltd, Fougera, and Pharmaderm, and is included in twenty NDAs. It is available from four suppliers. Additional details are available on the NEOMYCIN SULFATE profile page.
The generic ingredient in NEOMYCIN SULFATE is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.
The generic ingredient in NEOMYCIN SULFATE is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.
Summary for 065220
| Tradename: | NEOMYCIN SULFATE |
| Applicant: | Adrastea Pharma |
| Ingredient: | neomycin sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065220
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 065220 | ANDA | XGen Pharmaceuticals DJB, Inc. | 39822-0310 | 39822-0310-5 | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (39822-0310-5) / 1 TABLET in 1 BLISTER PACK (39822-0310-7) |
| NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 065220 | ANDA | Solaris Pharma Corporation | 73473-901 | 73473-901-05 | 100 TABLET in 1 BOTTLE, PLASTIC (73473-901-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Jul 28, 2006 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
